Why Science? | ICH E10 Choosing Clinical Trial Control Groups

The control design determines which biases are addressed and which treatment effect can be estimated. The choice is linked to the objective, disease, available therapy, outcome, duration and ethical context.

The scientific value of e10 makes control-group choice a question of interpretation appears when the clinical question, ethical duty and evidence decision remain connected. The control design determines which biases are addressed and which treatment effect can be estimated. The choice is linked to the objective, disease, available therapy, outcome, duration and ethical context. Keep this boundary visible: Control-group choice must match the exact clinical question and ethical context.

A strong science note separates observation from interpretation. Trace e10 makes control-group choice a question of interpretation from clinical question through comparison, conduct, analysis and supported claim. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Next chapter

The official page says E10 assists applicants in choosing a control group and explains related design and conduct issues and what each design can demonstrate. A current receipt records the May 2001 final guidance and applicable regional rules.

For fda describes e10 as guidance for trials intended to demonstrate efficacy, a reliable conclusion depends on both participant experience and the controlled study system. The official page says E10 assists applicants in choosing a control group and explains related design and conduct issues and what each design can demonstrate. A current receipt records the May 2001 final guidance and applicable regional rules. Preserve this guardrail: Similarity between groups does not by itself prove effectiveness or equivalence.

A strong science note separates observation from interpretation. Challenge ethics, assay sensitivity, constancy and bias behind fda describes e10 as guidance for trials intended to demonstrate efficacy. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Participants receive the investigational treatment or an inert presentation alongside appropriate background care. Randomisation and blinding can reduce bias, while rescue treatment and stopping rules protect participants.

A trustworthy account of placebo control estimates effect beyond expectation and background change keeps design, conduct, analysis and interpretation in one traceable route. Participants receive the investigational treatment or an inert presentation alongside appropriate background care. Randomisation and blinding can reduce bias, while rescue treatment and stopping rules protect participants. Remember: External controls carry comparability and confounding risks.

A strong science note separates observation from interpretation. Reconstruct placebo control estimates effect beyond expectation and background change from protocol rationale, historical evidence and treatment-group operations. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

When participants and investigators know that no trial treatment is given, expectations and co-interventions may differ. Objective outcomes or blinded assessment can reduce some bias, but the limitation remains explicit.

The scientific value of a no-treatment control can be informative but difficult to blind appears when the clinical question, ethical duty and evidence decision remain connected. When participants and investigators know that no trial treatment is given, expectations and co-interventions may differ. Objective outcomes or blinded assessment can reduce some bias, but the limitation remains explicit. Keep this boundary visible: Non-inferiority conclusions depend on assay sensitivity and a justified margin.

A strong science note separates observation from interpretation. Reassess a no-treatment control can be informative but difficult to blind after a change in standard care, endpoints, population or rescue practice. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Several doses can show whether response changes with dose and help identify a useful range. A flat pattern is interpretable only if doses, adherence, population, endpoints and study conduct make the comparison sensitive.

For dose-response designs compare multiple exposure levels, a reliable conclusion depends on both participant experience and the controlled study system. Several doses can show whether response changes with dose and help identify a useful range. A flat pattern is interpretable only if doses, adherence, population, endpoints and study conduct make the comparison sensitive. Preserve this guardrail: Control-group choice must match the exact clinical question and ethical context.

A strong science note separates observation from interpretation. Trace dose-response designs compare multiple exposure levels from clinical question through comparison, conduct, analysis and supported claim. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Both groups receive active therapies and the design tests a difference. The comparator dose, regimen and use must be appropriate, and blinding or blinded assessment protects evaluation where feasible.

A trustworthy account of active-control superiority asks whether the new treatment performs better keeps design, conduct, analysis and interpretation in one traceable route. Both groups receive active therapies and the design tests a difference. The comparator dose, regimen and use must be appropriate, and blinding or blinded assessment protects evaluation where feasible. Remember: Similarity between groups does not by itself prove effectiveness or equivalence.

A strong science note separates observation from interpretation. Challenge ethics, assay sensitivity, constancy and bias behind active-control superiority asks whether the new treatment performs better. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The margin is justified from historical evidence and clinical judgement before the trial. The design depends strongly on assay sensitivity, adherence, outcome quality and consistency with the setting in which the active control previously worked.

The scientific value of non-inferiority asks whether unacceptable loss can be excluded appears when the clinical question, ethical duty and evidence decision remain connected. The margin is justified from historical evidence and clinical judgement before the trial. The design depends strongly on assay sensitivity, adherence, outcome quality and consistency with the setting in which the active control previously worked. Keep this boundary visible: External controls carry comparability and confounding risks.

A strong science note separates observation from interpretation. Reconstruct non-inferiority asks whether unacceptable loss can be excluded from protocol rationale, historical evidence and treatment-group operations. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A two-sided region defines differences small enough to be considered clinically unimportant. Demonstrating no statistically significant difference is not the same as demonstrating equivalence.

For equivalence requires effects to stay within two justified bounds, a reliable conclusion depends on both participant experience and the controlled study system. A two-sided region defines differences small enough to be considered clinically unimportant. Demonstrating no statistically significant difference is not the same as demonstrating equivalence. Preserve this guardrail: Non-inferiority conclusions depend on assay sensitivity and a justified margin.

A strong science note separates observation from interpretation. Reassess equivalence requires effects to stay within two justified bounds after a change in standard care, endpoints, population or rescue practice. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Historical trials, registries or real-world data can provide a comparator in selected settings. Differences in eligibility, care, outcome definition, timing and data quality can create confounding that analysis cannot automatically remove.

A trustworthy account of external controls use information collected outside concurrent randomisation keeps design, conduct, analysis and interpretation in one traceable route. Historical trials, registries or real-world data can provide a comparator in selected settings. Differences in eligibility, care, outcome definition, timing and data quality can create confounding that analysis cannot automatically remove. Remember: Control-group choice must match the exact clinical question and ethical context.

A strong science note separates observation from interpretation. Trace external controls use information collected outside concurrent randomisation from clinical question through comparison, conduct, analysis and supported claim. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The design, population, outcomes and conduct must be capable of distinguishing effectiveness from ineffectiveness. Placebo-controlled superiority often demonstrates this directly; some active-control designs rely on prior and current evidence.

The scientific value of assay sensitivity means the trial could detect an effective treatment appears when the clinical question, ethical duty and evidence decision remain connected. The design, population, outcomes and conduct must be capable of distinguishing effectiveness from ineffectiveness. Placebo-controlled superiority often demonstrates this directly; some active-control designs rely on prior and current evidence. Keep this boundary visible: Similarity between groups does not by itself prove effectiveness or equivalence.

A strong science note separates observation from interpretation. Challenge ethics, assay sensitivity, constancy and bias behind assay sensitivity means the trial could detect an effective treatment. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Past estimates of active-control effect should remain relevant to the new trial’s population, endpoints, background care and conduct. Changes in clinical practice can weaken this assumption and need explicit evaluation.

For the constancy assumption supports some active-control interpretations, a reliable conclusion depends on both participant experience and the controlled study system. Past estimates of active-control effect should remain relevant to the new trial’s population, endpoints, background care and conduct. Changes in clinical practice can weaken this assumption and need explicit evaluation. Preserve this guardrail: External controls carry comparability and confounding risks.

A strong science note separates observation from interpretation. Reconstruct the constancy assumption supports some active-control interpretations from protocol rationale, historical evidence and treatment-group operations. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A concealed allocation process makes treatment groups comparable in expectation. Stratification or covariate adjustment can improve precision, but they do not replace sound randomisation when randomisation is feasible.

A trustworthy account of randomisation protects comparison from systematic allocation differences keeps design, conduct, analysis and interpretation in one traceable route. A concealed allocation process makes treatment groups comparable in expectation. Stratification or covariate adjustment can improve precision, but they do not replace sound randomisation when randomisation is feasible. Remember: Non-inferiority conclusions depend on assay sensitivity and a justified margin.

A strong science note separates observation from interpretation. Reassess randomisation protects comparison from systematic allocation differences after a change in standard care, endpoints, population or rescue practice. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Participants, investigators, assessors and analysts can be blinded according to the design. When treatments look or behave differently, double-dummy methods or blinded endpoint committees may protect critical decisions.

The scientific value of blinding protects behaviour, care and assessment from expectation appears when the clinical question, ethical duty and evidence decision remain connected. Participants, investigators, assessors and analysts can be blinded according to the design. When treatments look or behave differently, double-dummy methods or blinded endpoint committees may protect critical decisions. Keep this boundary visible: Control-group choice must match the exact clinical question and ethical context.

A strong science note separates observation from interpretation. Trace blinding protects behaviour, care and assessment from expectation from clinical question through comparison, conduct, analysis and supported claim. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Serious irreversible harm, effective therapy and participant vulnerability matter. Placebo may be inappropriate when withholding established treatment exposes participants to unacceptable risk, though specific justified situations may remain.

For ethics shape whether placebo or delayed treatment is acceptable, a reliable conclusion depends on both participant experience and the controlled study system. Serious irreversible harm, effective therapy and participant vulnerability matter. Placebo may be inappropriate when withholding established treatment exposes participants to unacceptable risk, though specific justified situations may remain. Preserve this guardrail: Similarity between groups does not by itself prove effectiveness or equivalence.

A strong science note separates observation from interpretation. Challenge ethics, assay sensitivity, constancy and bias behind ethics shape whether placebo or delayed treatment is acceptable. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Access to rescue protects participants but creates intercurrent events that the estimand and analysis must address. The protocol connects rescue criteria, data collection and interpretation rather than treating rescue as missing data by default.

A trustworthy account of rescue medication and withdrawal rules affect the treatment question keeps design, conduct, analysis and interpretation in one traceable route. Access to rescue protects participants but creates intercurrent events that the estimand and analysis must address. The protocol connects rescue criteria, data collection and interpretation rather than treating rescue as missing data by default. Remember: External controls carry comparability and confounding risks.

A strong science note separates observation from interpretation. Reconstruct rescue medication and withdrawal rules affect the treatment question from protocol rationale, historical evidence and treatment-group operations. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Visit schedules, follow-up, adherence support, outcome assessment and background care are kept comparable between groups. Unequal attention or measurement can create a treatment-looking difference unrelated to pharmacology.

The scientific value of operational similarity protects the comparison appears when the clinical question, ethical duty and evidence decision remain connected. Visit schedules, follow-up, adherence support, outcome assessment and background care are kept comparable between groups. Unequal attention or measurement can create a treatment-looking difference unrelated to pharmacology. Keep this boundary visible: Non-inferiority conclusions depend on assay sensitivity and a justified margin.

A strong science note separates observation from interpretation. Reassess operational similarity protects the comparison after a change in standard care, endpoints, population or rescue practice. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The record includes guidance version, objective and estimand, control type and rationale, ethical analysis, comparator regimen, historical evidence if used, margin if applicable, randomisation, blinding, background care, rescue, assay sensitivity, conduct, analysis, limitations and supported claim.

For a complete e10 receipt reconstructs the comparison argument, a reliable conclusion depends on both participant experience and the controlled study system. The record includes guidance version, objective and estimand, control type and rationale, ethical analysis, comparator regimen, historical evidence if used, margin if applicable, randomisation, blinding, background care, rescue, assay sensitivity, conduct, analysis, limitations and supported claim. Preserve this guardrail: Control-group choice must match the exact clinical question and ethical context.

A strong science note separates observation from interpretation. Trace a complete e10 receipt reconstructs the comparison argument from clinical question through comparison, conduct, analysis and supported claim. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter